Clinical trial · no report yet · Phase 3
MAPKeeper 301
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- NCT07562152 ↗
- Recruiting
- Immuneering Corporation
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma
- Interventions
- Atebimetinib; GnP; mGnP
- Arms
- Atebimetinib + mGnP · Experimental
- GnP · Active comparator
- Enrollment
- 510 (estimated)
- Primary outcomes
- Overall Survival
- Sponsor
- Immuneering Corporation
- Start
- Jun 5, 2026
- Primary completion
- Jun 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07562152 · updated Oct 16, 2026